Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: Recognition sites present on the A1 loop and A3 domains of von Willebrand factor

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 1, 1998, Pages 91-97

  Mohri, H ^a   Hisanaga, S ^b   Mishima, A ^a   Fujimoto, S ^b   Uezono, S ^c   Okubo, T ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Miyazaki Kohnan Hospital   (Japan)

Author keywords

Collagen binding domain; Glycoprotein Ib binding domain; Inhibitor; Von Willebrand disease

Indexed keywords

AUTOANTIBODY; COLLAGEN; GLYCOPROTEIN IB; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; BLEEDING TIME; CASE REPORT; COLLAGEN SYNTHESIS; DISEASE CLASSIFICATION; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

EID: 0031952804     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199801000-00012     Document Type: Article

References (23)

1. Cooney KA, Ginsburg D, Ruggeri ZM. von Willebrand disease. In: Loscalzo J, Schafer AI (editors). Thrombosis and Hemorrhage. Boston: Blackwell Scientific Publications, Inc.; 1994. pp. 657-662.
2. Van Genderen PJJ, Vink T, Michiels JJ, van't Veer MB, Sixma JJ, van Vliet HDM. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84: 3378-3383.
3. Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, et al. Acquired von Willebrand disease associated with multiple myeloma: characterization of an inhibitor to von Willebrand factor. Blood Coag Fibrinol 1995; 6: 561-566.
4. Mohri H, Noguchi T, Kodama F, Itoh A, Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987; 87: 663-668.
5. Richard C, Cuadarador MA, Prieto M, Batlle J, Lopez Fernandez MF, Rodriguez Salazar ML, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990; 35: 114-117.
6. Duke WW. The reaction of blood platelets to hemorrhagic disease: description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. J Am Med Assoc 1910; 55: 1185-1191.
7. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson JA. A method for assaying von Willebrand factor (Ristocetin cofactor). Thromb Diath Haemorrh 1975; 43: 303-306.
8. Brosstad F, Kjonniksen I, Ronning B, Stormorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986; 55: 276-281.
9. Fracker DJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6 tetrachloro 3a,6a diphenyl-glycoluril. Biochem Biophys Res Commun 1978; 80: 849-857.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analy Biochem 1976; 72: 248-254.
11. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 1983; 131: 2895-2902.
12. Andrew RK, Gorman JJ, Booth WJ, Castaldi PA, Berndt MC. Cross-linking of a monomeric 39/34 kDa dispase fragment of von Willebrand factor (Leu-480/ Val-481-Gly-718) to the N-terminal region of the - chain of membrane glycoprotein Ib on intact platelets with Bis (sulfosuccimidyl) suberate. Biochemistry 1989; 28: 8317-8326.
13. Girma J-P, Chopek MW, Titani K, Davie EW. Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of platelet-binding domain. Biochemistry 1986; 25: 3156-3163.
14. Marti T, Roesselet S, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 1987; 26: 8099-8109.
15. Ruggeri ZM, DeMarco L, Gatti L, Bader R, Montgomery RR. Platelet have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1-12.
16. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-602.
17. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-17367.
18. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262: 13835-13841.
19. Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews R. Identification of aspartic acid-514 through glutamic acid-542 as a glycoprotein Ib-complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry 1992; 31: 11144-11151.
20. Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1991; 266: 18172-18178.
21. Hoylaerts MF, Nuyts K, Peerlink K, Deckmyn H, Vermylen J. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. Biochem J 1995; 306: 453-463.
22. Scott JP, Montogomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991; 266: 8149-8155.
23. Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry 1986; 25: 8357-8361.